Key result
Blocking EPCR reduces circulating activated protein C by ~88% after thrombin infusion.
Answers are grounded in this paper and cite their sources.
Endothelial cell protein C receptor (EPCR) augments protein C activation by the thrombin-thrombomodulin complex about 5-fold in vitro. Augmentation is EPCR concentration dependent even when the EPCR concentration is in excess of the thrombomodulin. EPCR is expressed preferentially on large blood vessel endothelium, raising questions about the importance of protein C-EPCR interaction for augmenting systemic protein C activation. In these studies, this question was addressed directly by infusing thrombin into baboons in the presence or absence of a monoclonal antibody to EPCR that blocks protein C binding. Activated protein C levels were then measured directly by capturing the enzyme on a monoclonal antibody and assaying with chromogenic substrate. Blocking protein C-EPCR interaction resulted in about an 88% decrease in circulating activated protein C levels generated in response to thrombin infusion. Leukocyte changes, fibrinogen consumption, fibrin degradation products, and vital signs were similar between the animals infused with thrombin alone and those infused with thrombin and the anti-EPCR antibody. The results indicate that EPCR plays a major role in protein C activation and suggest that defects in the EPCR gene might contribute to increased risk of thrombosis.
No takes yet. Share an insight, caveat, or question.
Taylor et al. (2001) studied Protein C activation / thrombosis model. Anti-EPCR monoclonal antibody plus thrombin infusion vs. Thrombin infusion alone was evaluated on Circulating activated protein C levels generated in response to thrombin infusion (88% decrease). Blocking protein C-EPCR interaction with a monoclonal antibody reduced circulating activated protein C levels by ~88% following thrombin infusion in baboons.
Synapse has enriched 10 related papers. Consider them for comparative context: